84 related articles for article (PubMed ID: 6395920)
1. [Metastatic breast cancer: controlled trial of chemotherapy with and without hormones].
Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Magdelenat H; Asselain B; Pouillart P
Bull Cancer; 1984; 71(5):432-41. PubMed ID: 6395920
[TBL] [Abstract][Full Text] [Related]
2. [Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial].
Jouve M; Palangie T; Dorval T; Garcia-Giralt E; Asselain B; Coutant M; Magdelenat H; Pouillart P
Bull Cancer; 1987; 74(3):249-60. PubMed ID: 3304479
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
4. [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].
Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Tada A; Ueno K; Yamazaki H; Nakamura T; Ito Y; Inagaki J
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):327-32. PubMed ID: 2494947
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
7. [Disseminated breast carcinoma. Study of activity of immunotherapy with BCG and duration of the phase of intensive chemotherapy. Results of a randomized trial (author's transl)].
Pouillart P; Palangie T; Jouve M; Garcia-Giralt E; Magdelenat H; Asselain B
Bull Cancer; 1981; 68(1):6-18. PubMed ID: 7013868
[TBL] [Abstract][Full Text] [Related]
8. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C, methotrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant advanced breast cancer--a randomized control study.
Tashiro H; Nomura Y
Anticancer Res; 1995; 15(5B):2229-37. PubMed ID: 8572630
[TBL] [Abstract][Full Text] [Related]
10. [Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer].
Cavalli F; Beer M; Martz G; Jungi WF; Alberto P; Obrecht JP; Mermillod B; Brunner KW
Schweiz Med Wochenschr; 1982 May; 112(22):774-83. PubMed ID: 7048518
[TBL] [Abstract][Full Text] [Related]
11. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
[TBL] [Abstract][Full Text] [Related]
12. [A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer].
Ferrero JM; Namer M; Dufour JF; Largillier R; Creisson A; Teissier E; Machiavello JC; Lallement M; Monticelli J; Abbes M
Bull Cancer; 1997 Jan; 84(1):10-6. PubMed ID: 9180853
[TBL] [Abstract][Full Text] [Related]
13. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
14. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
15. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
Assikis V; Buzdar A; Yang Y; Smith T; Theriault R; Booser D; Valero V; Walters R; Singletary E; Ames F; Hortobagyi G
Cancer; 2003 Jun; 97(11):2716-23. PubMed ID: 12767083
[TBL] [Abstract][Full Text] [Related]
16. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
17. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
[TBL] [Abstract][Full Text] [Related]
18. [Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
Tamura H; Kojima M; Kobayashi H; Ando J; Oka S; Fujisaki M; Wada N; Imoto S; Ikeda T
Gan To Kagaku Ryoho; 2000 Jul; 27(7):993-1002. PubMed ID: 10925684
[TBL] [Abstract][Full Text] [Related]
19. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
20. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
